ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.599,57
-0,46%
S&P 500
5.222,68
0,16%
US Dollar vs BRL
5,1568
0,37%
Bitcoin
61.767,69
1,59%
Brent Oil
82,585
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) Notícias

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRLD
DataHoraFonteTítuloCódigoCompanhia
09/05/202408:01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
09/05/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202408:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
07/05/202408:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202408:01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202417:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202417:35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202418:45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
04/03/202420:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202418:05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202419:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202418:05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202418:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
11/12/202311:34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202317:10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202317:05Business WirePrelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202313:30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
29/08/202309:30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
03/08/202309:00GlobeNewswire Inc.Prelude Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
21/06/202317:17Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:PRLDPrelude Therapeutics Inc
21/06/202317:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:PRLDPrelude Therapeutics Inc
31/05/202309:30GlobeNewswire Inc.Prelude Therapeutics To Participate in Jefferies Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
24/05/202317:55Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:PRLDPrelude Therapeutics Inc
18/05/202308:00GlobeNewswire Inc.Prelude Therapeutics Announces Pricing of Public OfferingNASDAQ:PRLDPrelude Therapeutics Inc
17/05/202317:08GlobeNewswire Inc.Prelude Therapeutics Announces Launch of Proposed Public OfferingNASDAQ:PRLDPrelude Therapeutics Inc
08/05/202309:30GlobeNewswire Inc.Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations UpdateNASDAQ:PRLDPrelude Therapeutics Inc
08/05/202309:12Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202310:47Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202310:42Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:PRLDPrelude Therapeutics Inc
28/04/202309:47Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:PRLDPrelude Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRLD

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
BHIA3
Grupo Casas Bahia ON
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PETZ3
Pet Center Comercio E Pa... ON
BOV
LREN3
LOJAS RENNER ON
BOV
TELB4
TELEBRAS PN
BOV
GUAR3
GUARARAPES ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados